Clinical Trial of Efficacy and Safety of Divaza for Adjustment of Oxidative Disorders in Patients With Cerebral Atherosclerosis

PHASE4CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

April 12, 2018

Primary Completion Date

April 11, 2019

Study Completion Date

April 11, 2019

Conditions
Cerebral Atherosclerosis
Interventions
DRUG

Divaza

Oral administration.

DRUG

Placebo

Oral administration.

Trial Locations (10)

115516

Moscow City Clinical Hospital after V.M. Buyanov, Moscow

119049

State Budgetary Institution of Healthcare of the City of Moscow City Clinical Hospital No. 1 named after. N.I. Pirogov Moscow Department of Health, Moscow

119435

Federal State Budgetary Institution Federal Research and Clinical Center of Physical-Chemical Medicine Federal Medical Biological Agency, Moscow

119992

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow

141060

"Limited Liability Company Family policlinic no. 4", Korolyov

150000

"Federal State Budgetary Educational Institution of Higher Education Yaroslavl State Medical University of the Ministry of Healthcare of the Russian Federation", Yaroslavl

150030

State Institution of Health of the Yaroslavl Region Clinical Hospital No. 8, Yaroslavl

150062

"State budgetary institution of health care of the Yaroslavl region Regional Clinical Hospital", Yaroslavl

600023

"The state budgetary health care institution of the Vladimir region Regional Clinical Hospital", Vladimir

1253678

"Federal State Budget Scientific Institution Scientific Center of Neurology", Moscow

Sponsors
All Listed Sponsors
lead

Materia Medica Holding

INDUSTRY

NCT03485495 - Clinical Trial of Efficacy and Safety of Divaza for Adjustment of Oxidative Disorders in Patients With Cerebral Atherosclerosis | Biotech Hunter | Biotech Hunter